Overview

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide subjects continued access to valbenazine for the treatment of chorea associated with Huntington disease.

Phase:

Phase 3

Details

Lead Sponsor:

Neurocrine Biosciences

Collaborator:

Huntington Study Group